Pluri (NASDAQ:PLUR) Trading 1.1% Higher – Should You Buy?

Posted by Stanley Muller on Aug 11th, 2026

Shares of Pluri Inc. (NASDAQ:PLUR – Get Free Report) traded up 1.1% on Monday . The company traded as high as $1.8466 and last traded at $1.84. Approximately 14,944 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 29,346 shares. The stock had previously closed at $1.82.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 23rd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Check Out Our Latest Report on Pluri

Pluri Stock Performance

The firm has a market capitalization of $19.85 million, a P/E ratio of -0.41 and a beta of 0.67. The business has a fifty day moving average of $1.98 and a 200-day moving average of $2.84.

Pluri (NASDAQ:PLUR – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.11. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.66 million.

Institutional Investors Weigh In On Pluri

A hedge fund recently bought a new position in Pluri stock. Jane Street Group LLC purchased a new position in Pluri Inc. (NASDAQ:PLUR – Free Report) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri at the end of the most recent quarter. Institutional investors and hedge funds own 16.59% of the company’s stock.

Pluri Company Profile

(Get Free Report)

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.